The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
SLEEP 2026 | Looking ahead to SLEEP 2026: highlights and key themes
Romy Hoque, MD, FAASM, Emory University School of Medicine, Atlanta, GA, discusses the upcoming SLEEP 2026 meeting. Prof. Hoque highlights the expected advances in the treatment of hypersomnia, new developments in obstructive sleep apnea, the impact of artificial intelligence, and more. This interview took place at the 40th annual meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, MD.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, I think, you know, SLEEP 2026 will be in Baltimore, Maryland. It’s going to be a really well-attended meeting. There’s going to be a lot of attendees who are basic scientists, clinical researchers, clinicians, and, you know, in this year’s meeting, we’re going to have a lot of advances in the treatment of hypersomnia, including the treatment of narcolepsy and idiopathic hypersomnia...
Well, I think, you know, SLEEP 2026 will be in Baltimore, Maryland. It’s going to be a really well-attended meeting. There’s going to be a lot of attendees who are basic scientists, clinical researchers, clinicians, and, you know, in this year’s meeting, we’re going to have a lot of advances in the treatment of hypersomnia, including the treatment of narcolepsy and idiopathic hypersomnia. We’ve seen a lot of advances in the pharmacology of treating these disorders and new drug trials. Well, drug trial information will be presented. We’re excited to hear about these results and what they mean for the care of the patients that we see. And then also in terms of obstructive sleep apnea, CPAP remains our cornerstone treatment, but other therapies have become important in the treatment of patients with sleep apnea, including neurostimulation devices and the glucagon-like peptide receptor agonist medications and the weight loss they produce. So we have a lot of information on that and the management of those medications within sleep medicine practice and the use of neurostimulation devices. And then in terms of artificial intelligence and wearable technologies, we’re seeing new data on advances in home sleep apnea testing and just wearable consumer products for sleep evaluation as well. So there’s a lot of data that’s going to be presented at the meeting. So it’s really going to be a very good meeting. Well, I think the clinical practice will be really impacted by the new medications we have available for the treatment of hypersomnias, the central disorders of hypersomnias. And so I’m really excited to hear about these new medications and their impact on wake promotion and the results they’ve achieved through their clinical trial. So that’ll be interesting. Also, you know, we’re also looking into phenotyping OSA and endotyping OSA in terms of different subcategories and developing strategies in terms of treating OSA in different ways because not all OSA patients are the same. There will be some invited lectures on the endotyping of obstructive sleep apnea in patients. So that’ll be very interesting. And then also biomarker technology for the central disorders of hypersomnolence and use of REM sleep without atonia and the evaluation of neurodegenerative disease. So those are exciting areas.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
